Subtopic Deep Dive

Succinate Dehydrogenase Deficiency GIST
Research Guide

What is Succinate Dehydrogenase Deficiency GIST?

Succinate Dehydrogenase Deficiency GIST refers to a subtype of gastrointestinal stromal tumors characterized by succinate dehydrogenase (SDH) complex dysfunction, often due to germline SDHx mutations or epigenetic alterations, leading to unique tumor biology distinct from KIT/PDGFRA-driven GISTs.

SDH-deficient GISTs represent 7-10% of all GISTs and typically present in young patients with multifocal gastric tumors showing SDHB immunohistochemistry loss. Research identifies molecular subtypes via SDHA, SDHB, SDHC, and SDHD subunit analysis (Pantaleo et al., 2013, 104 citations). Over 20 key papers since 2009, including Stratakis and Carney (2009, 303 citations), define associations with Carney triad and Carney-Stratakis syndrome.

15
Curated Papers
3
Key Challenges

Why It Matters

SDH-deficient GISTs guide hereditary cancer screening protocols due to germline SDHx mutations in up to 30% of cases, enabling family risk assessment (Stratakis and Carney, 2009). SDHB immunohistochemistry serves as a diagnostic and prognostic marker, predicting indolent behavior despite imatinib resistance (Boikos et al., 2016). Altered chromosomal topology from SDH loss drives oncogenesis, informing targeted therapies beyond tyrosine kinase inhibitors (Flavahan et al., 2019). NCCN guidelines incorporate SDH testing for management (von Mehren et al., 2022).

Key Research Challenges

Diagnostic Accuracy of SDHB IHC

SDHB immunohistochemistry detects SDH deficiency but misses rare SDHA mutations, requiring subunit-specific testing (Pantaleo et al., 2013). False negatives occur in hypermethylation cases like Carney triad (Haller et al., 2014). Standardization across labs remains inconsistent.

Epigenetic Mechanism Elucidation

SDHC hypermethylation drives Carney triad GISTs without germline mutations, but upstream triggers are unclear (Haller et al., 2014). Chromosomal topology changes link to oncogenesis, yet reversible interventions are undeveloped (Flavahan et al., 2019).

Therapy Development for Imatinib Resistance

SDH-deficient GISTs resist KIT inhibitors, lacking effective alternatives despite quadruple wild-type definition (Pantaleo et al., 2014). Investigational therapies show limited efficacy in metastatic cases (Kelly et al., 2021).

Essential Papers

1.

Molecular Subtypes of<i>KIT/PDGFRA</i>Wild-Type Gastrointestinal Stromal Tumors

Sosipatros A. Boikos, Alberto S. Pappo, J. Keith Killian et al. · 2016 · JAMA Oncology · 383 citations

An observational study of WT GIST permitted the evaluation of a large number of patients with this rare disease. Three molecular subtypes with implications for prognosis and clinical management wer...

2.

The triad of paragangliomas, gastric stromal tumours and pulmonary chondromas (Carney triad), and the dyad of paragangliomas and gastric stromal sarcomas (Carney–Stratakis syndrome): molecular genetics and clinical implications

Constantine A. Stratakis, J A Carney · 2009 · Journal of Internal Medicine · 303 citations

Abstract. Carney triad (CT) describes the association of paragangliomas (PGLs) with gastrointestinal stromal tumours (GISTs) and pulmonary chondromas (PCH). A number of other lesions have been desc...

3.

Altered chromosomal topology drives oncogenic programs in SDH-deficient GISTs

William Flavahan, Yotam Drier, Sarah E. Johnstone et al. · 2019 · Nature · 248 citations

4.

The management of metastatic GIST: current standard and investigational therapeutics

Ciara M. Kelly, L. Gutiérrez Sainz, Ping Chi · 2021 · Journal of Hematology & Oncology · 223 citations

5.

Aberrant DNA hypermethylation of SDHC: a novel mechanism of tumor development in Carney triad

Florian Haller, Evgeny A. Moskalev, Fábio R. Faucz et al. · 2014 · Endocrine Related Cancer · 182 citations

Carney triad (CT) is a rare condition with synchronous or metachronous occurrence of gastrointestinal stromal tumors (GISTs), paragangliomas (PGLs), and pulmonary chondromas in a patient. In contra...

6.

Gastrointestinal stromal tumors: what do we know now?

Christopher L. Corless · 2014 · Modern Pathology · 179 citations

7.

NCCN Guidelines® Insights: Gastrointestinal Stromal Tumors, Version 2.2022

Margaret von Mehren, John M. Kane, Richard F. Riedel et al. · 2022 · Journal of the National Comprehensive Cancer Network · 107 citations

Gastrointestinal stromal tumors (GIST) are the most common type of soft tissue sarcoma that occur throughout the gastrointestinal tract. Most of these tumors are caused by oncogenic activating muta...

Reading Guide

Foundational Papers

Start with Stratakis and Carney (2009, 303 citations) for Carney triad/dyad genetics; Pantaleo et al. (2013, 104 citations) for SDH subunit analysis; Corless (2014, 179 citations) for GIST overview including SDH.

Recent Advances

Flavahan et al. (2019, 248 citations) on chromosomal topology; von Mehren et al. (2022, 107 citations) NCCN guidelines; Kelly et al. (2021, 223 citations) on metastatic management.

Core Methods

Core techniques: SDHB immunohistochemistry for screening (Boikos et al., 2016); SDHx gene sequencing and methylation PCR (Pantaleo et al., 2013; Haller et al., 2014); Hi-C sequencing for 3D genome changes (Flavahan et al., 2019).

How PapersFlow Helps You Research Succinate Dehydrogenase Deficiency GIST

Discover & Search

PapersFlow's Research Agent uses searchPapers and citationGraph to map 20+ papers from Boikos et al. (2016), revealing SDH subtype clusters via forward/backward citations. exaSearch uncovers related Carney triad studies; findSimilarPapers links Pantaleo et al. (2013) to quadruple WT GIST definitions.

Analyze & Verify

Analysis Agent employs readPaperContent on Flavahan et al. (2019) to extract chromosomal topology data, then runPythonAnalysis for survival statistics visualization with pandas. verifyResponse via CoVe cross-checks claims against Stratakis and Carney (2009); GRADE grading scores diagnostic evidence from Pantaleo et al. (2013) as high-quality.

Synthesize & Write

Synthesis Agent detects gaps in epigenetic therapies from Haller et al. (2014) and von Mehren et al. (2022). Writing Agent uses latexEditText for review drafting, latexSyncCitations for 10+ references, and latexCompile for publication-ready output; exportMermaid diagrams SDH mutation pathways.

Use Cases

"Run survival analysis on SDH-deficient vs KIT-mutant GIST cohorts from recent papers"

Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas survival curves from Boikos et al. 2016 data) → matplotlib plot of Kaplan-Meier estimates.

"Draft LaTeX review section on Carney triad SDH hypermethylation mechanisms"

Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations (Haller et al. 2014) → latexCompile → PDF with cited figure.

"Find code for SDHB IHC quantification in GIST pathology images"

Research Agent → paperExtractUrls → Code Discovery → paperFindGithubRepo → githubRepoInspect → runnable ImageJ script for stain analysis.

Automated Workflows

Deep Research workflow scans 50+ GIST papers via searchPapers → citationGraph → structured report on SDH subtypes with GRADE scores. DeepScan applies 7-step CoVe to verify epigenetic claims in Haller et al. (2014), flagging contradictions with Pantaleo et al. (2013). Theorizer generates hypotheses on SDH topology reversibility from Flavahan et al. (2019).

Frequently Asked Questions

What defines SDH-deficient GIST?

SDH-deficient GISTs are KIT/PDGFRA wild-type tumors with SDH complex dysfunction, diagnosed by SDHB IHC loss and confirmed via SDHx sequencing (Boikos et al., 2016).

What are main methods for studying SDH GIST?

Methods include SDHB immunohistochemistry, SDHx germline sequencing, DNA methylation arrays for SDHC, and Hi-C for chromosomal topology (Pantaleo et al., 2013; Haller et al., 2014; Flavahan et al., 2019).

What are key papers on SDH-deficient GIST?

Boikos et al. (2016, 383 citations) defines subtypes; Stratakis and Carney (2009, 303 citations) links to Carney syndromes; Flavahan et al. (2019, 248 citations) shows topology changes.

What open problems exist in SDH GIST research?

Challenges include therapies for imatinib-resistant cases, reversible epigenetic targeting in Carney triad, and quadruple WT subset classification beyond SDH/RAS (Pantaleo et al., 2014; Kelly et al., 2021).

Research Gastrointestinal Tumor Research and Treatment with AI

PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:

See how researchers in Health & Medicine use PapersFlow

Field-specific workflows, example queries, and use cases.

Health & Medicine Guide

Start Researching Succinate Dehydrogenase Deficiency GIST with AI

Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.

See how PapersFlow works for Medicine researchers